Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Financing Activities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Cash from Financing Activities over the past 16 years, most recently at -$402000.0 for Q2 2025.

  • Quarterly results put Cash from Financing Activities at -$402000.0 for Q2 2025, up 34.53% from a year ago — trailing twelve months through May 2025 was $6.4 million (down 14.45% YoY), and the annual figure for FY2025 was $6.4 million, down 14.45%.
  • Cash from Financing Activities for Q2 2025 was -$402000.0 at Lifecore Biomedical, Inc. \De\, up from -$6.8 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for LFCR hit a ceiling of $24.6 million in Q2 2023 and a floor of -$47.1 million in Q1 2022.
  • Median Cash from Financing Activities over the past 5 years was $3.4 million (2022), compared with a mean of $843833.3.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 506.36% in 2022 and later surged 611.23% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Cash from Financing Activities stood at $9.9 million in 2021, then fell by 10.82% to $8.8 million in 2022, then plummeted by 127.79% to -$2.4 million in 2023, then surged by 611.23% to $12.5 million in 2024, then tumbled by 103.21% to -$402000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were -$402000.0 (Q2 2025), -$6.8 million (Q1 2025), and $12.5 million (Q4 2024) per Business Quant data.